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Available online 24 December 2014The dried unripe fruit from Evodia rutaecarpa Benth., known asWu zhu yu in China, has long been
used in traditional Chinese medicine. In this research, we provide evidence that evodia fruit
extract activates peroxisome proliferator-activated receptor gamma (PPARγ) and, as identified
through HPLC fractionation and mass spectroscopy, the activating phytochemical is evodiamine.
Evodiamine was shown to bind to and activate PPARγ. It was also shown to activate PPARγ-
regulated gene expression in human hepatoma cells similar to known PPARγ ligands and that the
expression was blocked by a PPARγ specific antagonist.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The dried unripe fruit from Evodia rutaecarpa Benth., known
as Wu zhu yu in China, has long been used in traditional
Chinese medicine for the treatment of gastrointestinal disor-
ders (abdominal pain, dysentery), headache, amenorrhea, and
postpartum hemorrhage [1–3]. It also has a history of use as
a cardiotonic, a central stimulant with transient hyperten-
sive and positive inotropic and chronotropic effects [4,5]. In
phytochemical studies, the indoloquinazoline alkaloids from
the Evodia fruit (Evodiae fructus), evodiamine and rutaecarpine,ellular signal-regulated
P1, human fatty acid
taryl-CoA synthase 2;
LBD, ligand-binding
1; PPAR, peroxisome
alpha; TR-FRET, time-
, upstream activating
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un).
V. This is an open access article uhave been linked to these cardiotonic effects via activation of the
vanilloid receptor [6] and subsequent production of calcitonin
gene-related peptide [7]. These compounds also act on other
cardiovascular-related targets, rutaecarpine inhibits platelet
aggregation and evodiamine is a vasorelaxant [8,9].
Rutaecarpine and evodiamine have also been shown
to act at additional biological targets. In inflammation,
rutaecarpine directly inhibits COX-2 enzymatic activity [10],
while evodiamine inhibits COX-2 gene expression via an NF-
κB/Akt dependent pathway [11,12]. In aberrant cell growth,
evodiamine has been shown to inhibit cellular growth,
invasion, and metastasis of a wide variety of tumor cells,
while having little toxicity on normal human peripheral
blood cells [13]. In energy metabolism, evodiamine affects
biological targets involved in obesity and adipocyte matu-
ration while reducing diabetic complications in vivo [14,15].
It has been shown to block adipogenesis by activating ERK
thru EGFR activation and PKCα [15,16].
Peroxisome proliferator-activated receptor gamma (PPARγ)
is a ligand activated nuclear receptor that directly binds to
and regulates gene expression (for review see [17]). Its activationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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growth. In adipocytes, PPARγ activation stimulates lipids and
glucose uptake, leading to lipid storage. However, evodiamine
blocks PPARγ induced adipogenesis [18]. Therefore, evodiamine
is not an obvious PPARγ agonist. PPARγ ligands have a positive
effect on insulin action and improve glucose tolerance in diabetic
animals and humans, aswell as improvements in inflammation
and cognitive function [17]. These observations are consistent
with the effects seen for evodiamine in obesity, diabetic, and
Alzheimer's disease animal models [14,15,19].
In this research, we showed that evodia fruit extracts
demonstrate a robust response in a PPARγ luciferase reporter
assay. We further identified through HPLC fractionation and
mass spectroscopy that the activating phytochemical is
evodiamine.
2. Materials and methods
2.1. Chemicals and reagents
Evodiamine, rutaecarpine, and PPARγ agonists, rosiglitazone,
and troglitazone were obtained from Sigma Corporation
(St. Louis, MO). Evodiamine is a synthetic product (Sigma
Corp.) and as such is a mixture of chiral forms [20,21]. The
PPARγ antagonist, T0070907, and PPARα agonist, GW-7647,
were from Tocris Biologicals (Minneapolis, MN).
Vectors pGL4.35 9XUAS luc2P and pFN26A BIND, and
Fugene 6 were purchased from Promega Inc. (Madison, WI).
Restriction enzymes were from New England Biolabs (Ipswich,
MA), D-luciferin was from Biotium (Hayward, CA), and
LanthaScreen TR-FRET PPARγ competitive binding assay was
from Life Technologies (Grand Island, NY).
Dulbecco's minimum essential media (DMEM), Ham's F-
12K (Kaighn's, F12K) media, Dulbecco's phosphate buffered
saline (DPBS), fetal bovine serum (FBS), pennicillin/strepto-
mycin, and amphotericin B were purchased from Fisher
Scientific (Pittsburgh, PA); hygromycin from EMD Millipore
(Temecula, CA); and bovine serum albumin (BSA), G-418, and
β-mercaptoethanol (BME) were purchased from Sigma Corpo-
ration (St. Louis, MO).
RNeasy Plus Mini kit, and quantitative polymerase chain
reaction (qPCR) primer sets for human fatty acid binding protein
1 (FABP1), phosphoenolpyruvate carboxykinase 1 (PCK1), 3-
hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), and the
housekeeping gene, hypoxanthine phosphoribosyltransferase
1 (HPRT1) were purchased from Qiagen (Toronto, ON). First
strand cDNA synthesis kit, iScript, and the real-time qPCR kit,
SsoFast EvaGreen, were from Bio-Rad Laboratories (Hercules,
CA).
2.2. Evodia rutaecarpa fruit extracts
E. rutaecarpa fruit was harvested from plants cultivated in
China. The fruit was dried,milled into a homogenous feedstock,
and extracted at room temperature for 24 h in methanol or
chloroform using a ratio of 1:10 (fruit:solvent). The extract was
filtered, and solvent was removed by drying under nitrogen.
The resulting solids were quantified by mass, suspended in the
original extraction solvent, aliquoted, re-dried, sealed, and
stored at −80 °C. Before biological testing, the dried solidswere suspended in 70:30 DMSO:water, shaken for 2 h, and
diluted in cell culture media prior to assay.
Powdered E. rutaecarpa fruit extract was suspended in
methanol:water (50:50) at 50 mg/mL, sonicated for 10 min,
then filtered through a 0.45 μm PVDF membrane syringe filter
into an autosampler vial for UPLC fractionation and LC-MS
analysis.
2.3. UPLC fractionation and LC-MS analysis
Chromatographic separation was performed on an Acquity
UPLC-H chromatograph with photodiode array detector (PDA)
and XBridge Shield RP18 (5 μm, 4.6 × 250 mm) column. The
mobile phase solutions used for gradient separation were: A,
0.1% acetic acid in water and B, 0.1% acetic acid in acetonitrile.
Themobile phase gradient (A:B), at ambient temperature and a
flow rate of 0.8 mL/min, was initially set at 95:5 and linearly
changed to 0:100 from 0 to 30 min, held for 2 min, and then,
returned to initial conditions at 32.1 min and held till 35 min.
The injection volumewas 40 μL for both samples and standards
and the chromatogram recorded between 210 and 800 nm at a
1.2 nm resolution.
The effluent was split after the PDA, with the majority
going to a fraction collector configured for 96 well plates
with 2 mL/well volume. Fractions were collected at 20 s
intervals for 32 min. The plates were frozen at −80 °C over-
night, and the solvent was removed by freeze drying. The
sample plates were sealed and stored dry at −20 °C until
assayed for activity.
The remaining effluent was directed to a Waters Synapt G2
mass spectrometer equipped with an electrospray ion source
and operated at 25 V cone voltage. Accurate mass spectra were
collected in positive ion mode from m/z 100 to 1200 at 0.5 s/
scan,with alternating spectra collected at 0 V and 20 V collision
energy in the transfer cell (MSe mode). The mass spectra, UV
spectra, and fractions were time aligned for identification of
active compounds.
2.4. Plasmid constructs
To study the activation of PPARγ and PPARα in a
luciferase reporter assay, Gal4-PPARγ-ligand-binding do-
main (LBD) and Gal4-PPARα-LBD vectors were created in
a modified pFN26A (BIND) vector (Promega, Inc.). The
barnase gene was excised and a short cloning region (5′-
cgcagagctcaaaagcg-3′) was inserted at the PvuI/EcoRI site to
create pBIND3. The PPARγ-LBD (residues 203–477) was
qPCR amplified from human MGC: 5041 (pSPORT6; Open
Biosystems, Inc.) using forward and reverse primers 5′-
acgatcgaacagctgaatccagagtccgctga-3′ and 5′-tctagactagtacaag
tccttgtagatctcctgcaggagc-3′, incorporating pvuI and xbaI sites
at the 5′ and 3′ ends, respectively. The PPARγ-LBD fragment
was then ligated into the pBIND3 PvuI/XbaI site forming a
Gal4-PPARγ-LBD fusion protein. Similarly, the PPARα-LBD
(residues 201–468) vector was created using forward and
reverse primers, 5′-cgatcgcagacctcaaatctctgggc-3′ and 5′-
gaattcagtacatgtctctgtagatctcttgc-3′, to amplify the PPARα-
LBD from mouse MGC:18607 (Invitrogen). The PPARα-LBD
fragment was then ligated into the pBIND3 PvuI/EcoRI site
forming a Gal4-PPARα-LBD fusion protein.
Fig. 1. Effect of chloroform (CHL) and methanol (MetOH) evodia fruit extracts
(50 μg/ml) on PPARγ-LBD and PPARα-LBD luciferase assays. Positive controls
for the PPARα and PPARγ assays were GW-7647 (2 μM) and troglitazone
(10 μM), respectively. Luciferase activity was determined at 18 h. The data
shown is a representation of 3 separate experiments conducted under the same
conditions. Each column represents the mean ± SD, with n= 2.
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Human hepatoma (HepG2) and Chinese hamster ovary
(CHO-K1) cells were purchased from ATCC (Manasas, VA) and
grown in a 37 °C, 5% CO2 incubator in DMEM and F12K media,
respectively. All growthmediawas supplementedwith 10% FBS,
penicillin/streptomycin (100 U/100 μg/mL), and amphotericin
B (250 μg/mL).
Dual vector stable cell lines for PPARγ and PPARα assays
were generated by first transfecting CHO-K1 cells with pGL4.35
[luc2P/9XGAL4 UAS/Hygro] vector using Fugene 6 according to
manufacturer's instructions. Hygromycin (300 μg/mL) supple-
mentedmediawasused to screen formonoclonal cell lines 24h
after transfection, and selected monoclonal cell lines were
screened by dilution method until there was no further cell
death. The resulting stable cell line was maintained using
growth media supplemented with hygromycin (150 μg/mL).
PPARγ and PPARα cell lines were created by transfecting
the stable pGL4.35 [luc2P/9XGAL4 UAS/Hygro] vector CHO-K1Fig. 2. Effect of increasing concentrations of evodia fruit extract and the PPARγ
agonist, troglitazone, on the PPARγ luciferase reporter assay. Luciferase activity
was determined at 18 h. Data points are mean ± SD, n = 3. The graph is
representative of 3 separate experiments with similar results.cell linewith pBIND3Gal4-PPARγ-LBD or pBIND3Gal4-PPARα-
LBD vector and selecting for pBIND3 Gal4-PPAR-LBD con-
taining cells with G418 (600 μg/mL) supplemented media.
The resulting stable cell lines were maintained using growth
media supplemented with both hygromycin (150 μg/mL)
and G418 (300 μg/mL).
2.6. Luciferase reporter assay
Stably transfected CHO-K1 cells expressing the luciferase
reporter were plated (2 × 104 cells/well) in white-walled,
clear-bottom, 96-well plates and incubated overnight. The cells
were then serum starved for 24 h and treated with select
compounds at specified concentrations for 18 h in a 37 °C, 5%
CO2 incubator. Luciferase activity was quantified using a
luciferase assay kit (Biotium, Inc., Hayward, CA). Briefly, cells
were rinsed with 50 μL of DPBS, and then lysed with 20 μL lysis
buffer for 20 min at room temperature. D-luciferin was added
(100 μL/well) and light emission was read immediately on a
SpectraMax M5 spectrophotometer (Molecular Devices, Sun-
nyvale, CA). Data were plotted as relative light units (RLU)
against test compounds using GraphPad Prism software (San
Diego, CA).
2.7. LanthaScreen TR-FRET PPARγ competitive binding assay
To determine evodiamine binding to PPARγ-LBD, the
LanthaScreen TR-FRET (time-resolved fluorescence resonance
energy transfer) PPARγ competitive binding assay was per-
formed according to the manufacturer's instructions. Briefly,
increasing concentrations of select compounds were added to
an assaymixture of GST-PPARγ-LBD fusion protein (lacking the
DNA binding domain of PPARγ), fluoromone (a proprietary
fluorescent pan-PPARγ ligand), and a terbidium-labeled GST
antibody. Changes in fluoromone binding to the terbidium-
labeled LBD complex were measured using a SpectraMax M5
spectrophotometer with excitation wavelength set at 340 nm
and emissionwavelength at 520nm for fluorescein and 490nm
for terbium. The TR-FRET ratio was calculated by dividing the
emission signal at 520 nm by the emission signal at 490 nm.
Competition curves were plotted as TR-FRET ratio against
concentration of test compounds using GraphPad Prism
software.
2.8. Quantitative polymerase chain reaction
HepG2 cells were seeded at 1 × 106 cells/well in 6-well
culture plates and grown for 24 h then, the growth media was
replaced with media supplemented with 0.5% BSA in place of
FBS and the cells incubated for an additional 24 h. The cells
were then incubated for 18 hwith specific PPARγ agonists with
and without the addition of the PPARγ antagonist, T0070907.
The antagonist was added 20 min prior to the agonists. The
cells were rinsed with DPBS and total RNA purified using the
RNeasymini plus kit permanufacturer's instructions. Total RNA
was quantified using the A260/A280 ratio, diluted to 1 μg per
reaction, and reverse transcribed using the iScript cDNA
synthesis kit. Real-time qPCR reactions were completed using
SsoFast EvaGreen qPCRmix on a CFX96 Real-Time Thermocycler
(Bio-Rad). The reaction conditions were as follows: 95 °C for
30 s; 40 cycles of 58 °C for 5 sec; and 95 °C for 5 s. Fluorescent
Fig. 3. PPARγ luciferase activity (■) and LC-MS chromatogram (—) of evodia fruit extract. The extract (50mg/mL) was separated by reverse phase HPLC, and collected
fractions tested for activity in the PPARγ luciferase reporter assay. Accurate mass spectral analyses were performed to identify the predominant phytochemicals in
individual fractions.
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Cycle times of PCK1, FABP1, and HMGCS2 were normalized
to the housekeeping gene, HPRT1, prior to comparisons with
control samples.
3. Results and discussion
One difficulty associated with the analysis of phytochemi-
cals is their pleotropic nature [22,23]; they bind to and activate
multiple biological targets thus affecting multiple signalingFig. 4. The chemical structure of the primary phytochemicals in evodia frui
extract: evodiamine (A), rutaecarpine (B), and dehydroevodiamine (C).
Fig. 5. Effect of increasing concentrations of evodiamine, rutaecarpine, and
troglitazone in the PPARγ luciferase reporter assay. Luciferase activity was
determined at 18 h. Data points are mean ± SD, n = 3. The graph is
representative of 3 separate experiments with similar results.tpathways. In our phytochemical testing strategy, we employed
a luciferase reporter assay to isolate specific biological targets
from other interfering signals. In this research, we ligated
the specific ligand binding domains of PPARα and PPARγ to the
DNA binding domain of Gal4 allowing us to use the Gal4/
upstream activating sequence (UAS) signaling system [24]. The
Gal4-PPAR-LBD constructs were then co-transfected with a
UAS-luciferase construct into CHO-K1 cells. The results of the
luciferase reporter assays were limited to the activation of the
isolated LBD of PPARγ or PPARα. To further verify that the
luciferase signal was specific to the activation of the PPAR-LBD,
the evodia fruit extracts were also tested on a cell line stably
transfected with only the UAS-luciferase construct.
Evodia fruit extracts demonstrated a robust response in the
PPARγ-LBD luciferase assay that was not seen in either the
PPARα-LBD luciferase assay (Fig. 1) or the UAS only control cell
line (data not shown). Furthermore, the PPARγ luciferase
responsewas greater for the evodia fruit extract prepared using
the chloroform extraction method compared to the methanol
Fig. 6. Effect of increasing concentrations of the PPARγ antagonist, T0070907,
on evodiamine (20 μM)and troglitazone (10 μM)activity in the PPARγ luciferase
reporter assay. Luciferase activity was determined at 18 h. Data points are
mean ± SD, n= 3. The graph is representative of 3 separate experiments with
similar results.
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luciferase response that was concentration-dependent and
comparable in slope to that of the PPARγ agonist, troglitazone
(Fig. 2). The EC50 valueswere approximately 5 μg/mL for evodia
fruit extract and 5 μM (2 μg/mL) for troglitazone.
To determine which phytochemicals from the evodia fruit
extract might activate PPARγ, an extract of evodia fruit was
separated by reverse phase HPLC, and the fractions were tested
for activity in the PPARγ reporter assay. Accurate mass spectral
analysis of the effluent was conducted to identify the predom-
inant phytochemicals in the individual fractions. Fig. 3 is an
overlay of the LC-MS chromatographic data with the PPARγ
luciferase activity in the collected fractions.
The chromatographic peak at retention time of 23.12 min.,
corresponding to fraction 70, was shown to have the greatest
PPARγ luciferase activity. This fraction was analyzed by mass
spectrometry and yielded a spectrum containing a single
predominant ion at m/z 304.1443. This is consistent with an
elemental composition of C19H18N3O (calculated exact mass
304.1450, −2.3 ppm difference). The isotopic distribution
around theprotonatedmolecular ion also supports the assignedFig. 7. Effect of evodiamine, rutaecarpine, troglitazone, rosiglitanzone, and T0070907 in
Resonance Energy Transfer (TR-FRET) was performed. Troglitazone and rosiglitazo
mean ± SD, n = 2. The graph is representative of 2 separate experiments with si
4 parameter non-linear curve fit.formula. These data suggest that the observed ion is protonated
evodiamine. A reference standard of evodiamine was analyzed
for comparison and results confirmed that the retention times,
mass spectra, and UV–Vis spectra of evodiamine and the
unknown compound are identical; therefore, the compound
was determined to be evodiamine.
Two structurally related compounds of evodiamine,
dehydroevodiamine at 11.82 min and rutaecarpine at
24.49 min, showed no measureable PPARγ luciferase activity.
The chemical structures of evodiamine, dehydroevodiamine,
and rutaecarpine are presented in Fig. 4. These phytochemicals
have been identified as the main alkaloids in E. fructus [25], and
both evodiamine and rutaecarpine have been reported to have
biological activity (for review see [26]).
Using purified commercial preparations of evodiamine
and rutaecarpine, we confirmed that evodiamine yields a
concentration-dependent response in the PPARγ luciferase
reporter assay (Fig. 5). The rutaecarpine luciferase response
was much less than evodiamine and was not concentration
dependent. Furthermore, the rutaecarpine response in the
UAS-luciferase only cell line was similar to that in the PPARγ
reporter assay suggesting that the response was not specific to
PPARγ. Evodiamine had no response in this UAS-luciferase only
cell line (data not shown).
The specificity of the evodiamine response in the PPARγ
luciferase reporter assay was confirmed by blocking the
response with the PPARγ-LBD antagonist, T0070907 [27]. The
evodiamine (20 μM) response was inhibited by T0070907 in
a concentration-dependent manner (Fig. 6) similar to the
T0070907 inactivation of the agonist, troglitazone (10 μM).
To determine if the evodiamine PPARγ luciferase response
is through direct activation of the PPARγ-LBD we looked at
PPARγ-LBD binding using the LanthaScreen TR-FRET PPARγ
competitive binding assay. The PPARγ agonists, rosiglitazone
and troglitazone, and antagonist, T0070907, were shown
to decrease fluoromone binding to PPARγ-LBD (Fig. 7).
Evodiamine bindingwas shown to be concentration-dependent.
Rutaecarpine, which had aminimal response in the PPARγ-LBD
luciferase reporter assay, did not inhibit the fluoromone
binding to PPARγ-LBD (Fig. 7). The EC50 of troglitazone,
rosiglitazone, and T0070907 were 100 nM, 40 nM, and 1 μM,a competitive ligand binding assay for PPARγ-LBD. Time-Resolved Fluorescence
ne were PPARγ agonists and T0070907, a PPARγ antagonist. Data points are
milar results. Linear curve fits were completed with GraphPad Prism using a
Fig. 8. The effect of evodiamine (E, 20 and 100 μM), troglitazone (T, 10 μM) and
rosiglitazone (R, 10 μM) in the presence or absence of the PPARγ antagonist,
T0070907 (10 μM), on mRNA expression levels of PCK1 (a), FABP1 (b), and
HMGCS2 (c) in HepG2 cells as determined by qPCR. Vehicle (DMSO) treated
HepG2 cells were used as controls (C). Each column represents themean± SD,
n= 3.
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acts like a partial agonist and does not completely displace
fluoromone binding; however, we were unable to measure
activity at concentrations higher than 100 μM because
evodiamine interferes with the binding assay's fluorescent
signal.
Having shown that evodiamine binds to and activates the
PPARγ ligand binding domain, we next evaluated the effect ofevodiamine on PPARγ-dependent gene expression. HepG2
cells were treated with evodiamine, total RNA extracted, and
specific gene expression analyzed by qPCR. PPARγ agonists
have been shown to increase gene expression of FABP1, PCK1,
andHMGCS2 inHepG2 cells [28]. In these results, we show that
evodiamine up-regulated PCK1 which was inhibited by
T0070907 (Fig. 8a). Evodiamine was shown to slightly down-
regulate FABP1 gene expression (Fig. 8b), and to completely
down-regulate HMGCS2 expression (Fig. 8c). Both FABP1 and
HMGCS2 were further down-regulated with the addition
of T0070907. The PPARγ-LBD agonists, troglitazone and
rosiglitazone, were both shown to up-regulate the expres-
sion of all three genes and this up-regulation was blocked in
the presence of T0070907 (Fig. 8). The ability of evodiamine
to bind to and modulate a variety of cellular targets might
explain its varied effects on gene expression in HepG2 cells.
Additional research is required to further elucidate the effect
of evodiamine on PPARγ-responsive genes.
4. Conclusions
In summary, we have established that evodia fruit extract
activates PPARγ as shownby specific activation of a PPARγ-LBD
luciferase reporter assay and that the active phytochemical is
evodiamine. The PPARγ agonist activity of evodiamine was
confirmed in the luciferase assay and through a PPARγ-LBD
binding assay. The evodiamine response was concentration-
dependent and blocked by a specific PPARγ inhibitor,
T0070907. Additional research will be necessary to further
identify the effects of evodia fruit extract and evodiamine on
PPARγ-mediated gene expression and biological responses.
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